Sugi Predict

Sugi Predict / Compounds / SCHEMBL19950066

SCHEMBL19950066

SCHEMBL19950066

COc1cccc(F)c1-c1cc2c(NC(=O)c3cccc(N4CCN(C)CC4)c3)n[nH]c2cn1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K1 Q92918 7/20 0.68
▸ FGFR1 P11362 7/20 0.55
▸ FGFR2 P21802 4/20 0.53
▸ KIT P10721 3/20 0.51
▸ FLT3 P36888 3/20 0.51
▸ NTRK1 P04629 3/20 0.49
▸ PLK4 O00444 1/20 0.49
▸ DAPK3 O43293 1/20 0.49
▸ PRKCG P05129 1/20 0.49
▸ ROS1 P08922 1/20 0.49
▸ FER P16591 1/20 0.49
▸ LTK P29376 1/20 0.49
▸ WEE1 P30291 1/20 0.49
▸ FRK P42685 1/20 0.49
▸ MAPK8 P45983 1/20 0.49
▸ MST1R Q04912 1/20 0.49
▸ PTK2 Q05397 1/20 0.49
▸ TNK2 Q07912 1/20 0.49
▸ NTRK3 Q16288 1/20 0.49
▸ ALK Q9UM73 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19950132 0.93 MAP4K1 (0.74) MAP4K1FGFR1FGFR2KITFLT3
SCHEMBL30069603 0.92 MAP4K1 (0.60) MAP4K1FGFR1FGFR2KITFLT3
SCHEMBL19950152 0.92 MAP4K1 (0.60) MAP4K1FGFR1FGFR2KITFLT3
SCHEMBL19950223 0.92 MAP4K1 (0.57) MAP4K1FGFR1FGFR2KITFLT3
SCHEMBL19950373 0.92 MAP4K1 (0.59) MAP4K1FGFR1FGFR2NTRK1NTRK3
SCHEMBL30183675 0.92 MAP4K1 (0.59) MAP4K1FGFR1FGFR2NTRK1NTRK3
SCHEMBL31672293 0.91 MAP4K1 (0.57) MAP4K1FGFR1FGFR2KITFLT3
SCHEMBL19950263 0.91 MAP4K1 (0.57) MAP4K1FGFR1FGFR2KITFLT3
SCHEMBL30184050 0.90 MAP4K1 (0.56) MAP4K1FGFR1FGFR2KITFLT3
SCHEMBL19949952 0.90 MAP4K1 (0.56) MAP4K1FGFR1FGFR2KITFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12384778-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2025-08-12 — — US claimed
US-20240287059-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2024-08-29 — — US claimed
EP-4119558-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF Incyte Corporation (US) 2023-01-18 — — EP claimed
CN-109923114-B Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer 因赛特公司 2022-11-01 — — CN claimed
EP-3510032-A1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER Incyte Corporation (US) 2019-07-17 — — EP claimed
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 — — US claimed
WO-2018049200-A1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORPORATION (US) 2018-03-15 — — WO claimed
US-12384778-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2025-08-12 — — US disclosed
US-20240287059-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2024-08-29 — — US disclosed
US-11795166-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2023-10-24 — — US disclosed
US-11795166-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2023-10-24 — — US disclosed
US-11795166-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2023-10-24 — — US disclosed
CN-115819417-A Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer 因赛特公司 2023-03-21 — — CN disclosed
US-10266530-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2019-04-23 — — US disclosed
US-10266530-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2019-04-23 — — US disclosed
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-04-11 — — US disclosed
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-04-11 — — US disclosed
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 — — US disclosed
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 — — US disclosed
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12384778-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 MAP4K1 41/4885FGFR1 3938/4885FGFR2 4763/4885
US-11795166-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 MAP4K1 41/4885FGFR1 3938/4885FGFR2 4763/4885
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 MAP4K1 41/4885FGFR1 3938/4885FGFR2 4763/4885
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 MAP4K1 41/4885FGFR1 3938/4885FGFR2 4763/4885
US-10266530-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 MAP4K1 41/4885FGFR1 3938/4885FGFR2 4763/4885
US-20240287059-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 MAP4K1 41/4885FGFR1 3938/4885FGFR2 4763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.